Ubs Group Ag Coherus Bio Sciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 173,169 shares of CHRS stock, worth $128,145. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,169

Previous 185,540 6.67%

Holding current value

$128,145

Previous $320,000 43.75%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.99 - $1.8 $12,247 - $22,267	-12,371 Reduced 6.67%	173,169 $180,000
Q2 2024 Aug 13, 2024	BUY	$1.58 - $2.51 $100,598 - $159,811	63,670 Added 52.24%	185,540 $320,000
Q1 2024 May 13, 2024	SELL	$2.02 - $3.14 $45,361 - $70,511	-22,456 Reduced 15.56%	121,870 $291,000
Q4 2023 Feb 09, 2024	SELL	$1.59 - $3.85 $262,008 - $634,422	-164,785 Reduced 53.31%	144,326 $480,000
Q3 2023 Nov 09, 2023	BUY	$3.74 - $5.45 $1.15 Million - $1.67 Million	306,958 Added 14257.22%	309,111 $1.16 Million
Q2 2023 Aug 11, 2023	SELL	$3.79 - $8.3 $770,351 - $1.69 Million	-203,259 Reduced 98.95%	2,153 $9,000
Q1 2023 May 12, 2023	SELL	$5.89 - $10.52 $590,395 - $1.05 Million	-100,237 Reduced 32.79%	205,412 $1.41 Million
Q4 2022 Feb 08, 2023	BUY	$5.69 - $10.07 $1.48 Million - $2.63 Million	260,697 Added 579.95%	305,649 $2.42 Million
Q3 2022 Nov 10, 2022	SELL	$7.17 - $13.87 $510,116 - $986,795	-71,146 Reduced 61.28%	44,952 $432,000
Q2 2022 Aug 10, 2022	BUY	$5.86 - $13.23 $71,708 - $161,895	12,237 Added 11.78%	116,098 $841,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $653,354 - $981,826	-59,831 Reduced 36.55%	103,861 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $647,103 - $777,260	40,930 Added 33.34%	163,692 $2.61 Million
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $889,857 - $1.25 Million	70,178 Added 133.46%	122,762 $1.97 Million
Q2 2021 Aug 13, 2021	SELL	$12.95 - $15.41 $888,862 - $1.06 Million	-68,638 Reduced 56.62%	52,584 $727,000
Q1 2021 May 12, 2021	BUY	$14.42 - $21.39 $1.56 Million - $2.32 Million	108,462 Added 850.02%	121,222 $1.77 Million
Q4 2020 Feb 11, 2021	SELL	$16.56 - $18.94 $57,545 - $65,816	-3,475 Reduced 21.4%	12,760 $221,000
Q3 2020 Nov 12, 2020	SELL	$17.41 - $19.89 $137,869 - $157,508	-7,919 Reduced 32.79%	16,235 $298,000
Q2 2020 Jul 31, 2020	BUY	$14.43 - $19.16 $48,369 - $64,224	3,352 Added 16.11%	24,154 $431,000
Q1 2020 May 01, 2020	SELL	$11.67 - $22.53 $113,887 - $219,870	-9,759 Reduced 31.93%	20,802 $338,000
Q4 2019 Feb 14, 2020	SELL	$16.33 - $21.37 $44,450 - $58,169	-2,722 Reduced 8.18%	30,561 $550,000
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $540,198 - $774,505	-33,141 Reduced 49.89%	33,283 $674,000
Q2 2019 Aug 14, 2019	BUY	$13.1 - $22.1 $521,301 - $879,447	39,794 Added 149.43%	66,424 $1.47 Million
Q1 2019 May 14, 2019	SELL	$8.38 - $15.5 $1.52 Million - $2.81 Million	-181,404 Reduced 87.2%	26,630 $363,000
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $1.55 Million - $2.92 Million	179,492 Added 628.87%	208,034 $1.88 Million
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $168,761 - $236,499	11,679 Added 69.26%	28,542 $471,000
Q2 2018 Aug 14, 2018	SELL	$10.25 - $17.45 $656,399 - $1.12 Million	-64,039 Reduced 79.16%	16,863 $236,000
Q1 2018 May 15, 2018	BUY	$9.1 - $13.7 $637,000 - $959,000	70,000 Added 642.08%	80,902 $894,000
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $59,143 - $101,995	-7,083 Reduced 39.38%	10,902 $96,000
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $68,242 - $89,146	6,148 Added 51.94%	17,985 $239,000
Q2 2017 Aug 14, 2017	BUY	N/A	9,107 Added 333.59%	11,837 $171,000
Q1 2017 Nov 14, 2017	BUY	N/A	2,730	2,730 $58,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $57.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account